Effects and Prognostic Factors of Intensive Pulse Light Treatment for Meibomian Gland Dysfunction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of meibomian gland dysfunction
Exclusion Criteria:
- Medical conditions in which IPL is contraindicated (pregnancy, breastfeeding, lupus, and any major uncontrolled health problem).
- Contact lens wearer
- Previous ocular surgery
- Previous thermal treatment for dry eye disease (e.g. LipiFlow)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group 1
IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany).
IPL treatment is going to be administered to the skin below the lower eyelid.
Before treatment, the eyes will be protected with opaque goggles.
Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection.
The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
|
IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany).
IPL treatment is going to be administered to the skin below the lower eyelid.
Before treatment, the eyes will be protected with opaque goggles.
Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection.
The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline tearfilm break-up time at 2 weeks after the last treatment session
Time Frame: Baseline and 2 weeks after the last treatment session
|
Baseline and 2 weeks after the last treatment session
|
|
|
Change from baseline Oxford grade for corneal staining at 2 weeks after the last treatment session
Time Frame: Baseline and 2 weeks after the last treatment session
|
Oxford grade for staining was assessed on a scale of 0 to 5. It was scaled according to the degree of corneal staining as follow: 0 (absent), 1 (minimal), 2 (mild), 3 (moderate), 4 (marked), and 5 (severe)
|
Baseline and 2 weeks after the last treatment session
|
|
Change from baseline meibomian gland expressibility score at 2 weeks after the last treatment session
Time Frame: Baseline and 2 weeks after the last treatment session
|
The meibomian gland expressibility was assessed on a scale of 0 to 3 in five glands on the central lower lid.
It was scaled according to the number of glands expressible, as follows: 0 (all glands), 1 (three to four glands), 2 (one to two glands) and 3 (no glands)
|
Baseline and 2 weeks after the last treatment session
|
|
Change from baseline meibum quality score at 2 weeks after the last treatment session
Time Frame: Baseline and 2 weeks after the last treatment session
|
The meibum quality score were divided into the following four degrees: 0 (clear), 1 (cloudy), 2 (granular), and 3 (toothpaste)
|
Baseline and 2 weeks after the last treatment session
|
|
Change from baseline ocular surface disease index at 2 weeks after the last treatment session
Time Frame: Baseline and 2 weeks after the last treatment session
|
The ocular surface diseases index score range from 0 to 100 based on the result of standardized ocular surface disease index questionnaire.
Higher value represent worse subjective symptom.
|
Baseline and 2 weeks after the last treatment session
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019-04-066
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.